GlassScriptPhysician profile
Michael W Barrett
NPI 1588637771
$2,758.64
in general payments reported to CMS, 2019-2025
24 companies · $849 in 2025
The $849 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $133 · 2021: $399 · 2022: $258 · 2023: $337 · 2024: $598 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $381.20 | 2019-2025 | |
| Astellas Pharma US INC | $357.64 | 2019-2023 | Veozah |
| Novo Nordisk INC | $284.09 | 2021-2025 | Rybelsus, Ozempic |
| Amgen INC. | $274.05 | 2021-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $238.15 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Esperion Therapeutics, INC. | $211.30 | 2021-2025 | Nexletol |
| Lilly USA, LLC | $200.53 | 2022-2025 | Mounjaro, Jardiance, Trulicity |
| Abbott Laboratories | $173.17 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.89 | 2022-2025 | Jardiance |
| Corcept Therapeutics | $74.31 | 2025 | Korlym |
| Pfizer INC. | $71.78 | 2022-2023 | |
| Amarin Pharma, INC. | $63.44 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.25 | 2022-2025 | |
| Glaxosmithkline, LLC. | $53.85 | 2024 | Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $50.86 | 2024 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $30.68 | 2023 | Rexulti |
| Abbvie INC. | $30.40 | 2021-2025 | |
| Boston Scientific Corporation | $17.64 | 2024 | Wavewriter Alpha Prime 16 |
| Axsome Therapeutics, INC. | $14.19 | 2025 | Auvelity |
| Lundbeck LLC | $13.77 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $12.63 | 2025 | Voquezna |
| Allergan, INC. | $11.56 | 2020 | |
| Eyevance Pharmaceuticals LLC | $11.13 | 2021 | |
| Hikma Pharmaceuticals USA | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.